Further studies are needed to elucidate the molecular and immunological bases of HPD to improve the management of patients receiving ICI therapy
Further studies are needed to elucidate the molecular and immunological bases of HPD to improve the management of patients receiving ICI therapy. 3.1. shown clear survival benefits as single-agent or combination therapy when compared with standard chemotherapy in treatment-naive or previously treated patients.[1C7] However, increasing evidence has shown that these new immunotherapy drugs are associated…
